CNS: Translating Discoveries into Therapeutics Summit
23-24

October 2018

Austria

Vienna

About

We are pleased to invite you to the CNS: Translating Discoveries into Therapeutics Summit, scheduled for October 23-24, 2018 in Vienna, Austria. This premier B2B event provides the appropriate platform to engage and discuss ideas with your fellow peers, while facilitating a professional atmosphere and environment for good company representation and development. The summit will shed light on current challenges, best practices, and the inside view of the future in CNS translational discoveries and developments. We will discuss key findings, in...

We are pleased to invite you to the CNS: Translating Discoveries into Therapeutics Summit, scheduled for October 23-24, 2018 in Vienna, Austria. This premier B2B event provides the appropriate platform to engage and discuss ideas with your fellow peers, while facilitating a professional atmosphere and environment for good company representation and development. The summit will shed light on current challenges, best practices, and the inside view of the future in CNS translational discoveries and developments. We will discuss key findings, including critical insights, as well as recommendations for driving efficient strategies in the CNS landscape. It is an honour and privilege to invite you to participate in this Summit. We look forward to welcoming you in Vienna in October!

more info
Who Should Attend

Chief Executives, Directors, Vice Presidents, Heads, Leaders and Managers specialising in:

  • Central Nervous System
  • Neurodegenerative diseases
  • Computational Neuroscience
  • Translational Neuroscience
  • Neuropharmacology
  • Neuroimmunology
  • Neurology
  • Neuroengineering
  • Neuropharmaceuticals
  • Stem Cells
  • Neurodevices
  • Brain
  • Spinal Disorders
  • Blood Brain Barrier (BBB)
  • Arachnoid cysts
  • Autism
  • Catalepsy
  • Encephalitis
  • Infection
  • Meningitis
  • Multiple sclerosis
  • Alzheimer’s diseases
  • Parkinson's diseases
  • Sleep disorders
  • Neuroscience
  • Neuroimaging / Brain Imaging
  • Cognitive Neuroscience
  • Neuroinformatics
  • Neurobiology
  • Neurogenetics
  • Neurotechnology
  • Novel Neurotherapeutics
  • Central Nervous System Regenerative Medicine
  • Cell & Gene Therapies
  • Neurodiagnostics
  • Brain Stem
  • Biomarkers
  • Addiction
  • Attention deficit/hyperactivity disorder (ADHD)
  • Bipolar disorder
  • Depression
  • Epilepsy/Seizures
  • Locked-in syndrome
  • Migraine
  • Myelopathy
  • Huntington's disease
  • Tourette's diseases
Key Practical Learning Points of the Summit

Novel and emerging CNS targets and biomarkers
State of art CNS models and better understandable mechanism of action
Recent discoveries in neuro -imaging, -inflammation, -immunology, -degeneration, psychiatry and neurology
Strategic developments in neuro-pharmaceuticals, devices, and diagnostics
Advanced translational CNS strategies
Overcoming challenges to CNS drug delivery associated with blood-brain barrier (BBB)
Bridging science and tech to cover translational gap and to accelerate novel CNS therapeutics
Investment perspectives into neuroscience and new neurotech
Speakers
Dr. Bilada Bilican, US

Investigator II, Neuroscience

Novartis Institutes for BioMedical Research (NIBR)

Dr. Murali Gopalakrishnan, US

Head, Search & Evaluation Neuroscience

Abbvie

Dr. Silvia Gatti-McArthur, CH

Head, Research & Development CNS Innovation Center

Pierre Fabre

Dr. Qin Wang, US

Principal Scientist, Preclinical DMPK

Biogen Inc.

Dr. Michael Didriksen, DK

Senior Director - Schizophrenia/ Psychosis Biology Lead

Lundbeck A/S

Dr. Nuno Ribeiro Palha, FR

Preclinical Research Scientist / Neuropsychiatry Center for Therapeutic Innovation

Institut de Recherches SERVIER

Dr. Joël Mercier, BE

Associate Director, PET tracer Discovery

UCB

Dr. Roger N. Gunn, UK

Executive Vice President, Quantitative Data Sciences & Prof., Molecular Neuroimaging

Invicro, A Konica Minolta Company / Imperial College London

Dr. Kenneth Rhodes, US

Chief Scientific Officer

Yumanity Therapeutics

Dr. Martin Tolar, US

Founder, President & CEO

Alzheon

Marie McCarthy, IE

Senior Director Product Innovation / Information Technology

ICON plc

Dr. Frank S. Walsh, US

Founder

Ossianix

Dr. Winfried Neuhaus, AT

Head of the Biological Barriers Group & Principal Scientist

AIT, Center Health and Bioresources, Molecular Diagnostics

Sponsors and Partners

Media partner

Media partner

Media partner

Media partner

Media partner

Media partner